What is GALAPAGOS?
GALAPAGOS is a biotechnology company focused on the discovery and development of small molecule medicines. Headquartered in Belgium, the company operates within the clinical-stage sector, indicating a focus on advancing drug candidates through rigorous testing and regulatory processes. Its specialization in small molecule therapeutics positions it within a key segment of the pharmaceutical industry, aiming to create innovative treatments for various diseases.
How much funding has GALAPAGOS raised?
GALAPAGOS has raised a total of $295.5M across 3 funding rounds:
Stock Offering
$275.4M
Share Placement
$19.9M
Stock Offering
$178K
Stock Issuance/Offering (2015): $275.4M, investors not publicly disclosed
Share Placement (2020): $19.9M, investors not publicly disclosed
Stock Issuance/Offering (2021): $178K, investors not publicly disclosed
What's next for GALAPAGOS?
The recent major strategic investment into GALAPAGOS signals a pivotal moment for the company's growth trajectory. This influx of capital is likely to accelerate the development pipeline, potentially enabling further clinical trials and the expansion of its research and development capabilities. The enterprise-level backing suggests confidence from investors in GALAPAGOS's therapeutic approach and its potential to bring impactful medicines to market. Future endeavors will likely concentrate on advancing its lead candidates and exploring new therapeutic avenues.
See full GALAPAGOS company page
